Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009

Soeberg, MJ; Creighton, N; Currow, DC; Young, JM; Van Zandwijk, N

Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009

Soeberg, MJ Creighton, N Currow, DC

Young, JM Van Zandwijk, N

Permalink

Publication Type:: Journal Article
Citation:: Australian and New Zealand Journal of Public Health, 2016, 40 (3), pp. 255 - 262
Issue Date:: 2016-06-01

Closed Access

	Filename	Description	Size
	Soeberg_et_al-2016-Australian_and_New_Zealand_Journal_of_Public_Health.pdf	Published Version	282.42 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Soeberg, MJ	en_US
dc.contributor.author	Creighton, N	en_US
dc.contributor.author	Currow, DC https://orcid.org/0000-0003-1988-1250	en_US
dc.contributor.author	Young, JM	en_US
dc.contributor.author	Van Zandwijk, N	en_US
dc.date.available	2015-10-01	en_US
dc.date.issued	2016-06-01	en_US
dc.identifier.citation	Australian and New Zealand Journal of Public Health, 2016, 40 (3), pp. 255 - 262	en_US
dc.identifier.issn	1326-0200	en_US
dc.identifier.uri	http://hdl.handle.net/10453/105376
dc.description.abstract	© 2015 Public Health Association of Australia. Introduction: Malignant pleural mesothelioma (MPM) and malignant peritoneal mesothelioma (MPeM) are often grouped together in descriptive epidemiological analyses, resulting in limited understanding of epidemiological patterns for these tumour types. Methods: We studied patterns in the incidence, mortality and survival of people diagnosed with MPM (n=4,076) and MPeM (n=293) in New South Wales (NSW), Australia, 1972-2009. We also calculated 5-year relative survival for people diagnosed 1972-2006 followed up to 2007. We assessed patterns for each tumour type and histological subtype and, where possible, by combination of these categories. Results: Annual MPM cases steadily increased over time (n=208 in 2009). There was an increasing trend in the MPM age-standardised incidence rate from 1972 up to 1994. This rate increase has levelled off in the past 10 years. Since 1999, 11 cases of MPeM were diagnosed each year, on average. Five-year relative survival remained stable for MPM and MPeM. However, 5-year relative survival in 2002-2006 was substantially higher for people with MPM epithelioid histological subtype (11.7% [95%CI 6.8-18.2%]) compared to all other non-epithelioid histological subtypes (6.9% [95%CI 5.0-9.1%]), a 70% difference. Survival was also greater for women with MPM (13.4% [95%CI 8.5-19.4%]) compared to men (7.0% [95%CI 5.1-9.2%]). Interpretation: MPM incidence rates have stabilised since the mid-1990s, suggesting that maximum incidence levels have been reached. When more up-to-date data are available, survival estimates should be reanalysed to include people likely to benefit from the wide introduction of combination chemotherapy in 2007, including pemetrexed.	en_US
dc.relation.ispartof	Australian and New Zealand Journal of Public Health	en_US
dc.relation.isbasedon	10.1111/1753-6405.12503	en_US
dc.subject.classification	Public Health	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Mesothelioma	en_US
dc.subject.mesh	Peritoneal Neoplasms	en_US
dc.subject.mesh	Pleural Neoplasms	en_US
dc.subject.mesh	Disease-Free Survival	en_US
dc.subject.mesh	Drug Therapy, Combination	en_US
dc.subject.mesh	Registries	en_US
dc.subject.mesh	Incidence	en_US
dc.subject.mesh	Survival Analysis	en_US
dc.subject.mesh	Age Distribution	en_US
dc.subject.mesh	Sex Distribution	en_US
dc.subject.mesh	Adolescent	en_US
dc.subject.mesh	Adult	en_US
dc.subject.mesh	Aged	en_US
dc.subject.mesh	Middle Aged	en_US
dc.subject.mesh	New South Wales	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Male	en_US
dc.subject.mesh	Young Adult	en_US
dc.title	Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009	en_US
dc.type	Journal Article
utslib.citation.volume	3	en_US
utslib.citation.volume	40	en_US
utslib.for	1117 Public Health and Health Services	en_US
utslib.for	1605 Policy and Administration	en_US
utslib.for	1402 Applied Economics	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	closed_access
pubs.issue	3	en_US
pubs.publication-status	Published	en_US
pubs.volume	40	en_US

Abstract:

© 2015 Public Health Association of Australia. Introduction: Malignant pleural mesothelioma (MPM) and malignant peritoneal mesothelioma (MPeM) are often grouped together in descriptive epidemiological analyses, resulting in limited understanding of epidemiological patterns for these tumour types. Methods: We studied patterns in the incidence, mortality and survival of people diagnosed with MPM (n=4,076) and MPeM (n=293) in New South Wales (NSW), Australia, 1972-2009. We also calculated 5-year relative survival for people diagnosed 1972-2006 followed up to 2007. We assessed patterns for each tumour type and histological subtype and, where possible, by combination of these categories. Results: Annual MPM cases steadily increased over time (n=208 in 2009). There was an increasing trend in the MPM age-standardised incidence rate from 1972 up to 1994. This rate increase has levelled off in the past 10 years. Since 1999, 11 cases of MPeM were diagnosed each year, on average. Five-year relative survival remained stable for MPM and MPeM. However, 5-year relative survival in 2002-2006 was substantially higher for people with MPM epithelioid histological subtype (11.7% [95%CI 6.8-18.2%]) compared to all other non-epithelioid histological subtypes (6.9% [95%CI 5.0-9.1%]), a 70% difference. Survival was also greater for women with MPM (13.4% [95%CI 8.5-19.4%]) compared to men (7.0% [95%CI 5.1-9.2%]). Interpretation: MPM incidence rates have stabilised since the mid-1990s, suggesting that maximum incidence levels have been reached. When more up-to-date data are available, survival estimates should be reanalysed to include people likely to benefit from the wide introduction of combination chemotherapy in 2007, including pemetrexed.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/105376